NGEN
NASDAQ · Pharmaceuticals
Nervgen Pharma Corp
$1.35
+0.03 (+2.27%)
Open$1.36
Previous Close$1.32
Day High$1.38
Day Low$1.31
52W High$8.49
52W Low$3.20
Volume—
Avg Volume50.7K
Market Cap226.72M
P/E Ratio—
EPS$-0.36
SectorPharmaceuticals
Analyst Ratings
Strong Buy
8 analysts
Price Target
+825.2% upside
Current
$1.35
$1.35
Target
$12.49
$12.49
$8.17
$12.49 avg
$18.41
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 153.26M | 151.64M | 138.95M |
| Net Income | 33.69M | 27.50M | 27.23M |
| Profit Margin | 22.0% | 18.1% | 19.6% |
| EBITDA | 48.41M | 46.31M | 47.02M |
| Free Cash Flow | 29.41M | 26.14M | 25.26M |
| Rev Growth | +15.3% | +9.0% | +25.0% |
| Debt/Equity | 0.51 | 0.65 | 0.45 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $1,354.00 | -0.79% | 46.6 | 1.28T |
| JNJ | Johnson & Johnson | $276.22 | +1.43% | 40.8 | 656.45B |
| MRK | Merck & Co. Inc. | $146.73 | -0.14% | 147.8 | 362.53B |
| PFE | Pfizer Inc. | $29.39 | -1.64% | 41.4 | 167.12B |
| BMY | Bristol-Myers Squibb Co | $62.14 | -1.57% | 13.8 | 127.96B |
| ZTS | Zoetis Inc | $79.40 | -3.30% | 12.8 | 33.59B |